Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV6 | Q9H1D0 | 5/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15696998 | 0.91 | SIGMAR1 (0.38) | TRPV6SIGMAR1KDM4EALDH1A1KMT2A | |
| SCHEMBL18177837 | 0.91 | SIGMAR1 (0.41) | SIGMAR1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL14354978 | 0.90 | SIGMAR1 (0.44) | SIGMAR1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL18026602 | 0.90 | SIGMAR1 (0.44) | SIGMAR1KDM4EALDH1A1KMT2AMEN1 | |
| SCHEMBL23334402 | 0.88 | ALDH1A1 (0.37) | TRPV6KDM4EALDH1A1KMT2A | |
| SCHEMBL24453215 | 0.86 | SIGMAR1 (0.31) | TRPV6SIGMAR1KMT2A | |
| SCHEMBL20314481 | 0.84 | — | — | |
| SCHEMBL18032442 | 0.83 | HRH3 (0.39) | ALDH1A1 | |
| SCHEMBL12772414 | 0.83 | HRH3 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL22047673 | 0.82 | KMT2A (0.33) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME THERAPEUTICS LLC | 2024-01-18 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | Halia Therapeutics, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20220144804-A1 | Compound for Specifically Enhancing Spatial Coupling Degree of TRPV4-KCa2.3 Complex and Use thereof | JIANGNAN UNIVERSITY (CN) | 2022-05-12 | — | — | US | disclosed |
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| US-20210130345-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2021-05-06 | — | — | US | disclosed |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | GLENMARK PHARMACEUTICALS S.A. (CH) | 2020-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144804-A1 | Compound for Specifically Enhancing Spatial Coupling Degree of TRPV4-KCa2.3 Complex and Use thereof | TRPV4, TRPV2, TRPV3 | TRPV6 5/4885KDM1A 2956/4885SIGMAR1 2922/4885 |
| US-20200247800-A1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS AS NADPH OXIDASE INHIBITORS | NOX1, CYBB, NOX4 | TRPV6 3990/4885KDM1A 3652/4885SIGMAR1 3131/4885 |
| US-20210130345-A1 | BENZIMIDAZOLE DERIVATIVES, PREPARATION METHODS AND USES THEREOF | CDK6, CDK4, CDK3 | TRPV6 3529/4885KDM1A 645/4885SIGMAR1 4625/4885 |
| US-11053238-B2 | Benzimidazole derivatives, preparation methods and uses thereof | CDK6, CDK4, CDK3 | TRPV6 3529/4885KDM1A 645/4885SIGMAR1 4625/4885 |
| US-20230210853-A1 | TARGETED NEK7 INHIBITION FOR MODULATION OF THE NLRP3 INFLAMMASOME | NEK7, NLRP3, NOD1 | TRPV6 2644/4885KDM1A 4138/4885SIGMAR1 4107/4885 |
| US-20240018151-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | PIKFYVE, PIK3CD, PIK3R5 | TRPV6 1506/4885KDM1A 3183/4885SIGMAR1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.